MX2022016270A - Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma. - Google Patents

Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.

Info

Publication number
MX2022016270A
MX2022016270A MX2022016270A MX2022016270A MX2022016270A MX 2022016270 A MX2022016270 A MX 2022016270A MX 2022016270 A MX2022016270 A MX 2022016270A MX 2022016270 A MX2022016270 A MX 2022016270A MX 2022016270 A MX2022016270 A MX 2022016270A
Authority
MX
Mexico
Prior art keywords
bcl
antibody
inhibitor
combination
hodgkin
Prior art date
Application number
MX2022016270A
Other languages
English (en)
Inventor
Rainer Boxhammer
Konstantin Petropoulos
Peter Kelemen
Markus Rückert
Jan Endell
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2022016270A publication Critical patent/MX2022016270A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación describe una combinación farmacéutica de un anticuerpo anti-CD19 y un inhibidor de BCL-2 para el tratamiento de linfoma no Hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda.
MX2022016270A 2016-10-28 2019-04-26 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma. MX2022016270A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16196184 2016-10-28

Publications (1)

Publication Number Publication Date
MX2022016270A true MX2022016270A (es) 2023-02-15

Family

ID=57218739

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019004942A MX2019004942A (es) 2016-10-28 2017-10-27 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
MX2022016270A MX2022016270A (es) 2016-10-28 2019-04-26 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019004942A MX2019004942A (es) 2016-10-28 2017-10-27 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.

Country Status (24)

Country Link
US (1) US20190241656A1 (es)
EP (2) EP3532098B1 (es)
JP (2) JP7094950B2 (es)
KR (2) KR20230028571A (es)
CN (2) CN109890418B (es)
AU (1) AU2017348624A1 (es)
BR (1) BR112019008244A2 (es)
CA (1) CA3037246A1 (es)
CY (1) CY1124648T1 (es)
DK (1) DK3532098T3 (es)
ES (1) ES2871574T3 (es)
HR (1) HRP20210838T1 (es)
HU (1) HUE054496T2 (es)
IL (2) IL266216B2 (es)
LT (1) LT3532098T (es)
MX (2) MX2019004942A (es)
PL (1) PL3532098T3 (es)
PT (1) PT3532098T (es)
RS (1) RS62036B1 (es)
RU (1) RU2756405C2 (es)
SG (1) SG10202104036QA (es)
SI (1) SI3532098T1 (es)
WO (1) WO2018078123A1 (es)
ZA (1) ZA201903302B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909715VA (en) 2017-05-31 2019-11-28 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
JP2021535110A (ja) * 2018-08-31 2021-12-16 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2005012493A2 (en) 2003-07-31 2005-02-10 Immunomedics, Inc. Anti-cd19 antibodies
EA200800094A1 (ru) 2005-06-20 2008-06-30 Медарекс, Инк. Антитела cd19 и их использование
KR101397290B1 (ko) 2005-12-30 2014-05-21 메르크 파텐트 게엠베하 감소한 면역원성을 가지는 항-ｃｄ19 항체
SI2059536T1 (sl) 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
PT2066349E (pt) 2006-09-08 2012-07-02 Medimmune Llc Anticorpos anti-cd19 humanizados e respectiva utilização no tratamento de tumores, transplantação e doenças auto-imunes
WO2008150494A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
EP2211904B1 (en) 2007-10-19 2016-08-17 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
KR20110122859A (ko) 2009-02-23 2011-11-11 그렌마크 파머수티칼스 에스. 아. Ｃｄ１９에 결합하는 인간화된 항체 및 그것의 용도
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20120128586A1 (en) 2009-06-24 2012-05-24 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP4083071A3 (en) 2011-08-16 2023-02-22 MorphoSys AG Combination therapy with an anti-cd19 antibody and a purine analog
ES2909722T3 (es) 2011-08-16 2022-05-10 Morphosys Ag Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada
ES2818110T3 (es) * 2014-02-28 2021-04-09 Merck Sharp & Dohme Tratamiento del cáncer con una combinación que comprende dinaciclib
SG11201705476WA (en) * 2015-02-12 2017-09-28 Seattle Genetics Inc Combination therapy using a cd19-adc and vincristine

Also Published As

Publication number Publication date
BR112019008244A2 (pt) 2019-07-16
KR102500868B1 (ko) 2023-02-16
WO2018078123A1 (en) 2018-05-03
DK3532098T3 (da) 2021-05-25
CN109890418A (zh) 2019-06-14
JP7094950B2 (ja) 2022-07-04
AU2017348624A1 (en) 2019-03-28
HRP20210838T1 (hr) 2021-08-06
CY1124648T1 (el) 2022-07-22
IL266216B1 (en) 2023-05-01
PT3532098T (pt) 2021-06-17
SI3532098T1 (sl) 2021-12-31
EP3532098A1 (en) 2019-09-04
JP2022137089A (ja) 2022-09-21
PL3532098T3 (pl) 2022-01-31
LT3532098T (lt) 2021-06-25
IL266216A (en) 2019-06-30
ES2871574T3 (es) 2021-10-29
HUE054496T2 (hu) 2021-09-28
JP2019533682A (ja) 2019-11-21
US20190241656A1 (en) 2019-08-08
RS62036B1 (sr) 2021-07-30
CA3037246A1 (en) 2018-05-03
RU2019113370A3 (es) 2021-03-01
IL266216B2 (en) 2023-09-01
KR20190075942A (ko) 2019-07-01
RU2756405C2 (ru) 2021-09-30
MX2019004942A (es) 2019-08-12
ZA201903302B (en) 2021-04-28
CN118045175A (zh) 2024-05-17
RU2019113370A (ru) 2020-11-30
SG10202104036QA (en) 2021-05-28
EP3532098B1 (en) 2021-04-07
KR20230028571A (ko) 2023-02-28
CN109890418B (zh) 2024-03-08
EP3903821A1 (en) 2021-11-03
IL301786A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
MX2022016270A (es) Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
IL276830A (en) Anti-claudin 18.2 antibodies and uses thereof
SG11202007074PA (en) Anti-claudin 18.2 antibodies and uses thereof
EP3878863A4 (en) ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
MX2017016851A (es) Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos.
WO2016062722A8 (en) Combination
EP4360646A3 (en) Anti-tigit antibodies and methods of use
PH12017501318B1 (en) Anti-transthyretin antibodies
ZA202103061B (en) Anti-cldn18.2 antibody and uses thereof
MX2019006334A (es) Anticuerpos antitau y métodos de uso.
CY1122298T1 (el) Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του
WO2018081648A3 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2019005401A (es) Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
MX353589B (es) Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2022006154A (es) Combinaciones y sus usos.
MX2013014933A (es) Terapia de combinacion con un anticuerpo anti-cd19 y una mostaza de nitrogeno.
WO2015185875A3 (fr) Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs
EP3411504A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE-1 DIABETES
MY188849A (en) Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor
WO2018007922A3 (en) Anti-transthyretin antibodies
MX2021002888A (es) Combinaciones farmacéuticas para el tratamiento de tumores que comprenden un anticuerpo anti cúmulo de diferenciación 19 (cd19) y una célula asesina natural.
MX2019002960A (es) Oligonucleótidos modificados y métodos de uso.
WO2016170124A3 (en) Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior